Skip to content
← Index board

Health Optimization Index

Fisetin

Nick’s assessment
Promising
Research evidence
Not graded yet
Attention
23.3 / 100▲ Rising this week
6.8/ 10

BioHarmony score

Read Nick’s assessment Why it earned this rating

The 5.5 Neutral score reflects a real mechanism with thin and partly negative human translation. Fisetin is worth a structured 3-cycle trial for older adults with documented inflammatory load who already have sleep, training, and protein dialed in. It is not worth running as a daily longevity supplement for younger biohackers chasing healthspan; the Lee 2024 epigenetic-acceleration signal in adjacent senolytic class is a yellow flag until replicated. The Mayo AFFIRM-LITE primary results, when published, will likely move this score by 1 to 2 points in either direction. Bioavailability matters: use lipo or phytosomal formulations or skip the protocol.

✅ Best for: Older adults (50 plus) with documented inflammatory or metabolic load (elevated hs-CRP, joint stiffness, slow recovery, HbA1c drift) who already have the fundamentals locked in. Practitioners running structured 3-cycle trials with paired hs-CRP, ALT, and platelet biomarkers before and after. Users stacking fisetin with quercetin for senolytic class diversity on pulse days. People testing N-of-1 response over 6 to 12 months with qualitative readouts (Pulse Energy, Recovery Quality, Joint Comfort) rather than expecting acute effects. Geroscience-curious users who want exposure to the senolytic class but lack prescription access to dasatinib. The common thread is older, inflamed, fundamentals-first, and willing to track over months.

❌ Avoid if: Younger than 40 without documented inflammatory load; the Lee 2024 epigenetic-age-acceleration signal in dasatinib-quercetin users is a yellow flag for young senolytic users until replicated. On active chemotherapy without oncologist clearance, because senolytic interference with chemotherapy-induced senescence-as-tumor-suppressor is unmapped. On anticoagulants (warfarin, DOACs) or anti-platelet drugs (aspirin, clopidogrel, ticagrelor) without supervision; fisetin has measurable anti-platelet activity. Pregnant or breastfeeding (no safety data). On CYP2C9-sensitive medications (phenytoin, fluvastatin, losartan, sulfonylureas) or CYP1A2-sensitive medications (clozapine, theophylline). Active GI distress or recent surgery. Anyone using cheap unverified Cotinus coggygria extract instead of Novusetin or HPLC-verified lipo product.

Share your experience

Your answers are optional and help other readers — they never change my score. How community input works.

Tried it in real life?

How would you assess it?

Favorable is the strongest rating, followed by Promising, then Experimental. Overhyped means the claims outrun the evidence or interest is fading.

Make a 12-month prediction Will it rise or fall in the Index?

Choose a direction and your confidence. Correct predictions earn leaderboard points.

Your 12-month call on Fisetin
How sure are you?

Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →

Updated Sep 21, 2026 How the Index ranks →

Educational information, not medical advice. Ask a qualified clinician about risks and interactions. Independent ratings: no affiliate links, sponsored placements or paid rankings.